Sarepta Therapeutics' (SRPT) "Hold" Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "hold" rating reiterated by equities research analysts at Deutsche Bank Aktiengesellschaft in a report released on Monday, Marketbeat.com reports.

Other analysts have also issued reports about the company. Needham & Company LLC lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Friday. Jefferies Financial Group reduced their price target on Sarepta Therapeutics from $125.00 to $54.00 and set a "buy" rating for the company in a report on Monday, June 16th. Wolfe Research began coverage on shares of Sarepta Therapeutics in a research report on Tuesday, June 17th. They set a "peer perform" rating on the stock. William Blair reaffirmed a "market perform" rating on shares of Sarepta Therapeutics in a research note on Thursday. Finally, Piper Sandler downgraded Sarepta Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $70.00 to $36.00 in a research note on Monday, June 16th. One investment analyst has rated the stock with a sell rating, seventeen have issued a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $53.50.

Sarepta Therapeutics Trading Down 3.7%

Shares of SRPT traded down $0.52 during midday trading on Monday, hitting $13.57. The stock had a trading volume of 19,019,779 shares, compared to its average volume of 2,771,491. The business has a 50-day simple moving average of $28.42 and a two-hundred day simple moving average of $67.58. The firm has a market cap of $1.33 billion, a P/E ratio of -5.05 and a beta of 0.45. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a fifty-two week low of $11.95 and a fifty-two week high of $150.48.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The business had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business's quarterly revenue was up 80.2% on a year-over-year basis. During the same period last year, the business earned $0.73 EPS. As a group, equities analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. New York State Teachers Retirement System increased its holdings in shares of Sarepta Therapeutics by 3.3% during the first quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company's stock worth $5,065,000 after purchasing an additional 2,512 shares during the period. Exchange Traded Concepts LLC bought a new position in shares of Sarepta Therapeutics in the first quarter worth $479,000. GAMMA Investing LLC raised its stake in Sarepta Therapeutics by 4,682.8% in the first quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company's stock valued at $2,607,000 after purchasing an additional 39,991 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in Sarepta Therapeutics in the first quarter valued at about $821,000. Finally, Cetera Investment Advisers increased its stake in Sarepta Therapeutics by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 11,174 shares of the biotechnology company's stock valued at $1,359,000 after acquiring an additional 463 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.